Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidazole SCHEMBL17867609 | 0.86 | ALDH1A1 (0.37) | GPR119L3MBTL1USP2SMN1; SMN2CYP24A1 | |
| SCHEMBL1199386 | 0.82 | AHR (0.36) | GPR119CYP24A1CYP17A1TBXAS1 | |
| SCHEMBL14158754 | 0.82 | GPR119 (0.35) | GPR119L3MBTL1CYP24A1TBXAS1 | |
| SCHEMBL10359587 | 0.82 | TBXAS1 (0.36) | GPR119CYP24A1CYP17A1TBXAS1 | |
| SCHEMBL2262506 | 0.82 | ALDH1A1 (0.52) | GPR119USP2SMN1; SMN2FAAHPOLB | |
| SCHEMBL6899758 | 0.82 | L3MBTL1 (0.43) | GPR119L3MBTL1CYP24A1CYP17A1 | |
| SCHEMBL5063771 | 0.81 | L3MBTL1 (0.36) | GPR119L3MBTL1CYP24A1CYP17A1TBXAS1 | |
| SCHEMBL25392514 | 0.81 | CYP24A1 (0.35) | GPR119CYP24A1CYP17A1FAAHTBXAS1 | |
| Iodide SCHEMBL18143129 | 0.81 | GPR119 (0.34) | GPR119L3MBTL1CYP24A1TBXAS1 | |
| SCHEMBL21982074 | 0.81 | ELANE (0.36) | GPR119CYP24A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 889 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113943253-B | Dexmedetomidine hydrochloride preparation method of intermediate | 北京四环制药有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-119661811-A | Latent accelerator based on anhydride-tertiary amine dynamic ion pair, preparation method and application thereof | 江南大学 | 2025-03-21 | — | — | CN | claimed |
| WO-2025027521-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF AVIBACTAM AND INTERMEDIATE THEREOF | FRESENIUS KABI ONCOLOGY LTD. (IN) | 2025-02-06 | — | — | WO | claimed |
| CN-118546667-A | Self-lubricating slick water fracturing fluid and preparation method thereof | 延安鼎大工贸有限公司 | 2024-08-27 | — | — | CN | claimed |
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-09 | — | — | US | claimed |
| WO-2024024935-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE HAVING ANTINEOPLASTIC EFFECT | 第一三共株式会社 | 2024-02-01 | — | — | WO | claimed |
| EP-4286393-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2023-12-06 | — | — | EP | claimed |
| CN-117120516-A | Polyimide, resin composition, polyimide film, and method for producing same | 旭化成株式会社 | 2023-11-24 | — | — | CN | claimed |
| CN-115368694-B | Biomass-based reinforced polyvinyl alcohol composite material and preparation method thereof | 河北百展科技发展有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-116867795-A | Novel method for producing antibody-immunostimulant conjugate | 第一三共株式会社 | 2023-10-10 | — | — | CN | claimed |
| EP-0988290-B1 | CARBONYLDIIMIDAZOLES, THEIR ESTER DERIVATIVES AND METHOD FOR THEIR PRODUCTION | BASF AG (DE) | 2007-01-10 | — | — | EP | claimed |
| US-20060247341-A1 | Complexes of zinc with substituted amidines and guanidines and aliphatic carboxylates, e.g., Zn(1-methylimidazole)2(acetate)2 and Zn(tetramethylguanidine)2(formate)2; useful as catalysts for deblocking blocked isocyanates and in the production of urethanes and polyurethanes | KING INDUSTRIES, INC. | 2006-11-02 | — | — | US | claimed |
| WO-2006022899-A2 | ORGANOMETALLIC COMPOSITIONS AND COATING COMPOSITIONS | KING INDUSTRIES, INC. (US) | 2006-03-02 | — | — | WO | claimed |
| US-20060036007-A1 | Organometallic compositions and coating compositions | KING INDUSTRIES, INC. (US) | 2006-02-16 | — | — | US | claimed |
| EP-1218338-A1 | PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2002-07-03 | — | — | EP | claimed |
| EP-0563238-B1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORP (US) | 2002-05-22 | — | — | EP | claimed |
| US-20020042536-A1 | PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES | ABBOTT LABORATORIES | 2002-04-11 | — | — | US | claimed |
| WO-2001040163-A1 | A PROCESS FOR PRODUCING AMINE COMPOUND WITH t-BUTOXYCARBONYL GROUP | KOREA FINE CHEMICAL CO.,LTD. (KR) | 2001-06-07 | — | — | WO | claimed |
| WO-2001027074-A1 | PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES | ABBOTT LABORATORIES (US) | 2001-04-19 | — | — | WO | claimed |
| US-4189543-A | ALKYL IMIDAZOLE-N-CARBOXYLATE COMPOUNDS | THE DOW CHEMICAL COMPANY (US) | 1980-02-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150390-A1 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | PAICS, COASY, CDS2 | GPR119 1027/4885L3MBTL1 4350/4885USP2 3951/4885 |
| US-20020042536-A1 | PREPARATION OF AMINO-PROTECTED LYSINE DERIVATIVES | DNPEP, PHYKPL, KARS1 | GPR119 4311/4885L3MBTL1 1463/4885USP2 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.